Novo Nordisk Shares Droop Amid FDA Approval Uncertainties

Novo Nordisk shares are trading lower after the recent analyses of oral semaglutide (Wegovy in a pill) raised investor concerns over its pending FDA approval, despite promising clinical trial results.